Lifeboat Foundation

Biotechnology
Genome editing through CRISPR-Cas systems has the potential to correct genetic mutations that occur in diseased cells, such as cancer cells. However, the ability to selectively activate CRISPR-Cas systems in diseased cells is important to ensure that gene editing only occurs where it is wanted. Zhu et al. developed a system whereby gene editing could be activated by a magnetic field, thus allowing spatial control. The use of nanomagnets in their system also improved transduction into target cells in tumor-bearing mouse models. This approach could potentially allow the translation of CRISPR-Cas systems into therapeutic agents.

Nat. Biomed. Eng. 10.1038/s41551-018‑0318-7 (2018).

Very excited to join IdeaXme (http://radioideaxme.com/) as Longevity Ambassador, utilizing this wonderful media platform to help expand global awareness of the people engineering a future free of aging, disease, degeneration, and suffering.

He Jiankui has now presented his controversial work at a gene editing summit in Hong Kong. CRISPR expert Helen O’Neill of University College London was there.

The introduction of the gene editing tool CRISPR in 2007 was a revolution in medical science and cell biology. But even though the potential is great, the launch of CRISPR has been followed by debate about ethical issues and the technology’s degree of accuracy and side effects.

However, in a new study published in Cell, researchers from the Novo Nordisk Foundation Center for Protein Research have described how Cas12a, one of the CRISPR technologies, works at the molecular level. This makes it possible to fine-tune the gene-editing process to achieve specific desired effects.

“If we compare CRISPR to a car engine, what we have done is make a complete 3D map of the engine and thus gained an understanding of how it works. This knowledge will enable us to fine-tune the CRISPR engine and make it work in various ways—as a Formula 1 racer as well as an off-road truck,” says Professor Guillermo Montoya from the Novo Nordisk Foundation Center for Protein Research.

Showrunner Jeff Buhler has built a fascinating world around Martin’s story seeds, starting by setting the action within the foreseeable future, rather than in an incomprehensibly distant one. The invented technologies here are particularly intriguing, like the genetic modifications first officer Melantha Jhirl (Jodie Turner-Smith) has to make her better suited for space travel, or the cybernetics technician Lommie (Maya Eshet) uses to interface with machinery. Given the state of real-world technological developments in genetic engineering and research into brain-machine interfaces, the series feels plausible and grounded, even though it’s set in a spacefaring future.

The 10-episode space series adapts a 40-year-old George R.R. Martin novella.

Continue reading “Syfy’s Nightflyers asks whether humanity deserves to be saved” »

A couple of days ago, news about the first designer babies has shaken the world. A Chinese researcher, Jiankui He, and his team at the Southern University of Science and Technology of China have been recruiting couples in order to create the world’s first babies with artificially increased resilience to HIV. The embryos were modified using the CRISPR/Cas9 gene editing tool before being implanted in their mother.

According to the research lead, the twins were born healthy a few weeks ago, and genetic testing performed after they were born confirmed that the editing had actually taken place. While the academic community discusses whether it is acceptable or not to modify human genes, taking into account that the changes made will be inherited by these babies’ offspring and are now added to mankind’s genetic pool, I want to share my own views on designer babies.

Harvard University geneticist George Church says reaction to experiments has been “extreme”.

Some researchers say it’s time to allow gene editing, with careful regulation.